跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
OR-641
首页
药物
OR-641
OR-641
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules
申请人: MILLENNIUM PHARM INC
优先权: 2003
US
2 件公开
Compositions and methods for treating STAT-6 associated diseases or conditions
申请人: UNIV MCGILL
优先权: 2005
US
2 件公开
MUTATED PARVOVIRUS STRUCTURAL PROTEIN
申请人: 2A PHARMA AB
优先权: 2018
EP
Parvovirus structural protein for the treatment of autoimmune diseases
申请人: 2A PHARMA AB
优先权: 2018
CN
US
3 件公开
Biological markers for longevity and diseases and uses thereof
申请人: EINSTEIN COLL MED
优先权: 2005
US
Methods of treating cancer
申请人: GLAXOSMITHKLINE LLC
优先权: 2012
CN
US
3 件公开
COMPOSITIONS AND METHODS FOR MACROPHAGE-SELECTIVE MODULATION OF IL‑4/IL‑13-MEDIATED STAT6 SIGNALING
申请人: REVOLO BIOTHERAPEUTICS LTD
优先权: 2025
WO
DNA polymerase variant and application thereof
申请人: MGI TECH CO LTD
优先权: 2017
EP
US
2 件公开
药物
反馈